SEC Form 4 · accession 0001231919-26-000654
Werewolf Therapeutics, Inc. · HOWL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
RA Capital Healthcare Fund LP
10% Owner
RA CAPITAL MANAGEMENT, L.P.
10% Owner
Peter Kolchinsky
10% Owner
Rajeev M. Shah
10% Owner
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 6:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785530
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 12, 2026 | S | 159,119 | $0.40 | D | 4,917,566 | I | See footnotes |
| Common StockF1,F3,F4 | Jun 12, 2026 | S | 11,322 | $0.40 | D | 349,907 | I | See footnotes |
| Common StockF5,F2,F3 | Jun 15, 2026 | S | 120,216 | $0.39 | D | 4,797,350 | I | See footnotes |
| Common StockF5,F3,F4 | Jun 15, 2026 | S | 8,554 | $0.39 | D | 341,353 | I | See footnotes |
| Common StockF6,F2,F3 | Jun 16, 2026 | S | 139,686 | $0.37 | D | 4,657,664 | I | See footnotes |
| Common StockF6,F3,F4 | Jun 16, 2026 | S | 9,939 | $0.37 | D | 331,414 | I | See footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3814 to $0.4129 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
- F3RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
- F4Held directly by Nexus Fund II.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3757 to $0.3955 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3584 to $0.3906 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.